| Website | cytheris.com |
| Category | BioTech |
| Phone | 33-(0)-1-5888-3800 |
| Employees | |
| Founded | 1/99 |
| TOTAL | $45.7M |
| VENTURE FUNDING TOTAL | $45.7M |
| Series B, 10/06 CDC Enterprises ABN AMRO Private Equity AXA Private Equity Bioam Gestion Credit Agricole Private Equity T2C2 Capital Caisse de Depot et Placement du Quebec | $30.7M |
| Series D, 6/10 CDC Entreprises Bioam Gestion Caisse de Depot et Placement du Quebec CDC Innovation Crédit Agricole Private Equity Forbion Capital Partners | $15M |
Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).
